Krystal Biotech, Inc. (KRYS) stock analysis

In our weekly check, Krystal Biotech, Inc. is graded A (A to F). Of 17 checks on debt, profit, cash flow and trend: 15 pass, warnings: 2, red flags: 0.

Sector: Healthcare · Biotechnology

Strengths

Warning signs

Next earnings report: 2026-11-02

Similar companies

AXSM · ARWR · PTGX · KYMR · IBRX · TGTX

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks graded D or F lost a third of their value 2-3 times as often as those graded A or B.

Updated 2026-10-03

Open the full analysis